Literature DB >> 34159841

Clinical Trials of COVID-19 Therapies Should Account for Diabetes and Hyperglycemia.

David C Klonoff1, Jordan Messler2, Timothy Valk3, Ram Jagannathan4, Francisco J Pasquel4, Guillermo E Umpierrez4.   

Abstract

Complications of Coronavirus Disease 2019 (COVID-19) occur with increased frequency in people admitted to the hospital with diabetes or hyperglycemia. The increased risk for COVID-19 infections in the presence of these metabolic conditions is in part due to overlapping pathophysiologic features of COVID-19, diabetes, and glucose control. Various antiviral treatments are being tested in COVID-19 patients. We believe that in these trials, it will be useful to evaluate treatment effect differences in patients stratified according to whether they have diabetes or hyperglycemia. In this way, it will be possible to better facilitate development of antiviral treatments that are most specifically beneficial for the large subset of COVID-19 patients who have diabetes or hyperglycemia.

Entities:  

Keywords:  COVID-19; antiviral; clinical trial; diabetes; hospital; hyperglycemia

Mesh：

Substances：

Year:  2021        PMID： 34159841      PMCID： PMC8442178          DOI： 10.1177/19322968211013369

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN： 1932-2968


  57 in total

1.  Update on inpatient glycemic control in hospitals in the United States.

Authors:  Christine M Swanson; Daniel J Potter; Gail L Kongable; Curtiss B Cook
Journal:  Endocr Pract       Date:  2011 Nov-Dec       Impact factor: 3.443

2.  Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis.

Authors:  Mary Chester M Wasko; Helen B Hubert; Vijaya Bharathi Lingala; Jennifer R Elliott; Michael E Luggen; James F Fries; Michael M Ward
Journal:  JAMA       Date:  2007-07-11       Impact factor: 56.272

3.  Benchmarking glycemic control in u.s. Hospitals.

Authors:  Sophie Bersoux; Curtiss B Cook; Gail L Kongable; Jianfen Shu; Denise R Zito
Journal:  Endocr Pract       Date:  2014-09       Impact factor: 3.443

4.  Impact of blood glucose abnormalities on outcomes and disease severity in patients with severe sepsis: An analysis from a multicenter, prospective survey of severe sepsis.

Authors:  Shigeki Kushimoto; Toshikazu Abe; Hiroshi Ogura; Atsushi Shiraishi; Daizoh Saitoh; Seitaro Fujishima; Toshihiko Mayumi; Toru Hifumi; Yasukazu Shiino; Taka-Aki Nakada; Takehiko Tarui; Yasuhiro Otomo; Kohji Okamoto; Yutaka Umemura; Joji Kotani; Yuichiro Sakamoto; Junichi Sasaki; Shin-Ichiro Shiraishi; Kiyotsugu Takuma; Ryosuke Tsuruta; Akiyoshi Hagiwara; Kazuma Yamakawa; Tomohiko Masuno; Naoshi Takeyama; Norio Yamashita; Hiroto Ikeda; Masashi Ueyama; Satoshi Fujimi; Satoshi Gando
Journal:  PLoS One       Date:  2020-03-11       Impact factor: 3.240

5.  A role of glycation and methylation for SARS-CoV-2 infection in diabetes?

Authors:  Giovanni Sartore; Eugenio Ragazzi; Luca Faccin; Annunziata Lapolla
Journal:  Med Hypotheses       Date:  2020-09-03       Impact factor: 1.538

6.  Furin cleavage sites naturally occur in coronaviruses.

Authors:  Yiran Wu; Suwen Zhao
Journal:  Stem Cell Res       Date:  2020-12-09       Impact factor: 2.020

7.  CD14+ monocytes are vulnerable and functionally impaired under endoplasmic reticulum stress in patients with type 2 diabetes.

Authors:  Takuya Komura; Yoshio Sakai; Masao Honda; Toshinari Takamura; Kouji Matsushima; Shuichi Kaneko
Journal:  Diabetes       Date:  2009-12-03       Impact factor: 9.461

8.  Monocytopenia, monocyte morphological anomalies and hyperinflammation characterise severe COVID-19 in type 2 diabetes.

Authors:  Fawaz Alzaid; Jean-Baptiste Julla; Marc Diedisheim; Charline Potier; Louis Potier; Gilberto Velho; Bénédicte Gaborit; Philippe Manivet; Stéphane Germain; Tiphaine Vidal-Trecan; Ronan Roussel; Jean-Pierre Riveline; Elise Dalmas; Nicolas Venteclef; Jean-François Gautier
Journal:  EMBO Mol Med       Date:  2020-09-11       Impact factor: 12.137

9.  The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike.

Authors:  Yu Li; Ziding Zhang; Li Yang; Xianyi Lian; Yan Xie; Shen Li; Shuyu Xin; Pengfei Cao; Jianhong Lu
Journal:  iScience       Date:  2020-07-28

10.  Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study.

Authors:  Sebastiano Bruno Solerte; Francesca D'Addio; Roberto Trevisan; Elisabetta Lovati; Antonio Rossi; Ida Pastore; Marco Dell'Acqua; Elio Ippolito; Cristiana Scaranna; Rosalia Bellante; Silvia Galliani; Alessandro Roberto Dodesini; Giuseppe Lepore; Francesca Geni; Roberta Maria Fiorina; Emanuele Catena; Angelo Corsico; Riccardo Colombo; Marco Mirani; Carlo De Riva; Salvatore Endrio Oleandri; Reza Abdi; Joseph V Bonventre; Stefano Rusconi; Franco Folli; Antonio Di Sabatino; Gianvincenzo Zuccotti; Massimo Galli; Paolo Fiorina
Journal:  Diabetes Care       Date:  2020-09-29       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.